Understanding how cell membranes break during certain types of cell death and how glycine can help protect cells.

Molecular basis of plasma membrane rupture in lytic cell death and its inhibition by cytoprotective agent glycine

['FUNDING_OTHER'] · CASE WESTERN RESERVE UNIVERSITY · NIH-10930843

This study is looking at how a protein called NINJ1 causes cells to break apart during cell death, which can affect how our body fights infections and deals with inflammation, and by learning more about this process, the researchers hope to find new ways to protect cells using a substance called glycine.

Quick facts

Phase['FUNDING_OTHER']
Study typeNih_funding
SexAll
SponsorCASE WESTERN RESERVE UNIVERSITY (nih funded)
Locations1 site (CLEVELAND, UNITED STATES)
Trial IDNIH-10930843 on ClinicalTrials.gov

What this research studies

This research investigates the molecular mechanisms behind plasma membrane rupture (PMR) during lytic cell death, which is a critical process in both fighting infections and contributing to inflammatory diseases. The study focuses on a protein called NINJ1, which is responsible for causing PMR, and uses advanced imaging techniques like cryogenic electron microscopy to explore its structure and function. By understanding how NINJ1 works, researchers aim to identify ways to inhibit this process with the cytoprotective agent glycine, potentially leading to new therapeutic strategies for various diseases.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals suffering from inflammatory diseases or conditions where cell death plays a significant role.

Not a fit: Patients with non-inflammatory conditions or those not affected by cell death mechanisms may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that protect cells from damage during inflammatory responses, improving outcomes for patients with various diseases.

How similar studies have performed: While the specific approach of targeting NINJ1 in PMR is novel, similar research has shown promise in understanding cell death mechanisms and developing cytoprotective strategies.

Where this research is happening

CLEVELAND, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Cancers

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.